Dollar change +0.21
Percentage change 4.95	%

Peers: SSYS DDD CAMT MTLS WFRD DM PRLB PKOH FARO VIVS

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-10.43	Insider Own	20.39%	Shs Outstand	2.49M	Perf Week	27.51%
Market Cap	12.28M	Forward P/E	-	EPS next Y	-2.51	Insider Trans	23.48%	Shs Float	2.20M	Perf Month	78.00%
Enterprise Value	11.49M	PEG	-	EPS next Q	-0.79	Inst Own	5.87%	Short Float	6.99%	Perf Quarter	64.21%
Income	-12.54M	P/S	6.60	EPS this Y	76.76%	Inst Trans	52.76%	Short Ratio	1.30	Perf Half Y	34.44%
Sales	1.86M	P/B	2.77	EPS next Y	27.03%	ROA	-102.44%	Short Interest	0.15M	Perf YTD	27.14%
Book/sh	1.60	P/C	2.84	EPS next 5Y	-	ROE	-195.48%	52W High	8.60 -48.23%	Perf Year	4.81%
Cash/sh	1.57	P/FCF	-	EPS past 3/5Y	97.33% 83.21%	ROIC	-178.26%	52W Low	1.71 160.23%	Perf 3Y	-99.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	68.26% 33.18%	Gross Margin	13.81%	Volatility	11.33% 8.31%	Perf 5Y	-99.99%
Dividend TTM	-	EV/Sales	6.18	EPS Y/Y TTM	96.14%	Oper. Margin	-439.49%	ATR (14)	0.27	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	2.41	Sales Y/Y TTM	-40.47%	Profit Margin	-674.05%	RSI (14)	83.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.57	EPS Q/Q	74.64%	SMA20	37.11%	Beta	0.77	Target Price	28.00
Payout	-	Debt/Eq	0.88	Sales Q/Q	-82.42%	SMA50	44.32%	Rel Volume	2.54	Prev Close	4.24
Employees	20	LT Debt/Eq	0.76	Earnings	May 16	SMA200	42.21%	Avg Volume	118.74K	Price	4.45
IPO	Feb 13, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	-70.86% -44.83%	Trades		Volume	24,588	Change	4.95%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-12-19	Initiated	Ascendiant Capital Markets	Buy

Aug-15-25 07:00AM	SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition (GlobeNewswire)
Aug-07-25 06:35PM	Sensus Healthcare, Inc. (SRTS) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +7.64%
Aug-04-25 07:00AM	SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates (GlobeNewswire) +11.25%
Jul-22-25 05:15PM	Intuitive Surgical, Inc. (ISRG) Q2 Earnings and Revenues Top Estimates (Zacks) -5.76%
07:00AM	SINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices (GlobeNewswire)
08:30AM	Loading…
Jun-24-25 08:30AM	SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market (GlobeNewswire)
Jun-12-25 09:00AM	SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors (GlobeNewswire) +6.46%
May-22-25 07:00AM	SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market (GlobeNewswire) -7.57%
May-15-25 07:05AM	SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization (GlobeNewswire)
Apr-03-25 08:00AM	SINTX Technologies Announces Strategic Changes to Board of Directors (GlobeNewswire)
Mar-19-25 05:23PM	Sintx Technologies files to sell 3.01M shares of common stock for holders (SeekingAlpha)
08:00AM	SINTX Technologies Announces Publication of Study Confirming Superior Performance of Silicon Nitride in Cervical Spine Fusion (GlobeNewswire)
Mar-17-25 08:00AM	Sintx Technologies Announces Board Chairman Transition (GlobeNewswire) -8.77%
Feb-26-25 08:00AM	SINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -19.63%
Feb-20-25 06:15AM	SINTX Technologies Sells Technology Assesment and Transfer Subsidiary to Focus on Medical Device Market (GlobeNewswire)
06:00AM	Loading…
Feb-19-25 06:00AM	SINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial (GlobeNewswire) +70.92%
Dec-17-24 06:00AM	SINTX Technologies Secures Patent Allowance for Wide-Ranging Silicon Nitride Biomaterial Applications (GlobeNewswire)
Nov-21-24 06:00AM	SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment (GlobeNewswire) +15.59%
Nov-19-24 06:49AM	Sintx Technologies Initiates Stock Repurchase Program (TipRanks)
06:00AM	SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer (GlobeNewswire)
Nov-18-24 06:00AM	SINTX Technologies Announces Stock Repurchase Program (GlobeNewswire) +55.88%
Nov-14-24 06:00AM	SINTX Technologies Provides Positive Strategic Business Update for Q3 2024 (GlobeNewswire)
Oct-01-24 08:00AM	SINTX Announces Key Executive Promotions: Ryan Bock, PhD, Named Chief Technology Officer and Ann Kutsch Promoted to President of SINTX TA&T (GlobeNewswire)
Sep-20-24 08:00AM	Prodways and SINTX Announce Joint Webinar Stay Ahead of the Curve: "Innovations in Ceramic Manufacturing: The Role of 3D Printing" (GlobeNewswire)
Sep-19-24 08:00AM	SINTX Announces Completion of $3.1 Million ATM Equity Public Offering (GlobeNewswire)
Sep-09-24 08:00AM	SINTX Receives Notice of Allowance for United States Patent Application for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial (GlobeNewswire) +54.61%
Sep-05-24 08:00AM	SINTX Provides Strategic Update: Significant Cost Reductions, Extended Cash Runway, and Exploration of Strategic Partnerships (GlobeNewswire)
Aug-13-24 10:54PM	SINT Stock Earnings: SINTX Technologies Beats Revenue for Q2 2024 (InvestorPlace)
Aug-06-24 09:00AM	SINTX Technologies Announces Appointment of Eric K. Olson as Chief Executive Officer (GlobeNewswire)
Jun-18-24 09:00AM	SINTX Technologies to Explore Strategic Opportunities (GlobeNewswire)
09:00AM	Loading…
Jun-12-24 09:00AM	SINTX Technologies Regains Compliance with Nasdaq Bid Price Requirement (GlobeNewswire)
Jun-06-24 09:00AM	SINTX Technologies Receives Additional SBIR Contract for 3D Printing Technology (GlobeNewswire) -11.33%
May-29-24 09:00AM	SINTX TECHNOLOGIES SIGNS AGREEMENT TO ENTER KOREAN TECHNICAL CERAMICS SECTOR (GlobeNewswire) -15.73%
May-23-24 09:00AM	SINTX TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE MAY 28, 2024 (GlobeNewswire) -13.50%
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-20-24 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +32.82%
May-15-24 08:36AM	Castellum (CTM) Stock Down 16% Today? (InvestorPlace) +132.00%
08:05AM	Why Is Sintx Technologies (SINT) Stock Up 113% Today? (InvestorPlace)
07:57AM	Top Premarket Gainers (MT Newswires)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-14-24 09:52AM	SINT Stock Earnings: SINTX Technologies Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +41.75%
Apr-29-24 09:14AM	SINTX AND PRODWAYS AGREE ON CERAMIC SLURRY SUPPLY AND 3D PRINTING AGREEMENT (GlobeNewswire) +34.90%
Apr-03-24 09:00AM	SINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stock (GlobeNewswire) -43.77%
Mar-29-24 04:00PM	SINTX Technologies Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-28-24 06:52AM	SINT Stock Earnings: SINTX Technologies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
Mar-25-24 09:05AM	Why Is Sintx Technologies (SINT) Stock Down 31% Today? (InvestorPlace) -45.95%
09:00AM	SINTX Technologies Announces Pricing of $1.3 Million Public Offering of Common Stock (GlobeNewswire)
Mar-22-24 08:30AM	SINTX Technologies Announces Proposed Public Offering of Common Stock (GlobeNewswire) -31.99%
Feb-21-24 09:00AM	SINTX TECHNOLOGIES ENTERS INTO A SECOND LONG TERM SUPPLY AGREEMENT FOR THE AEROSPACE MARKET (GlobeNewswire)
Feb-02-24 02:33PM	SINTX Technologies Announces Closing of $4.0 Million Public Offering (GlobeNewswire)
Jan-31-24 09:20AM	SINTX Technologies Announces Pricing of $4.0 Million Public Offering (GlobeNewswire) -34.50%
07:59AM	Why Is SINTX Technologies (SINT) Stock Up 52% Today? (InvestorPlace)
Jan-30-24 04:01PM	SINTX SUBSIDIARY TECHNOLOGY ASSESSMENT & TRANSFER TO DEVELOP 3D PRINTING AND CMCs WITH DEVCOM-ARMY RESEARCH LABORATORY (GlobeNewswire) -13.69%
Jan-23-24 09:00AM	SINTX TECHNOLOGIES SHARES SELECT PRELIMINARY Q4 2023 AND FULL YEAR 2023 REVENUE UPDATE (GlobeNewswire)
Jan-04-24 09:00AM	SINTX TECHNOLOGIES SIGNIFICANTLY STRENGTHENS ITS ANTIPATHOGENIC PATENT PORTFOLIO (GlobeNewswire)
Nov-07-23 09:00AM	SINTX TECHNOLOGIES ENTERS A LONG-TERM SUPPLY AGREEMENT FOR AEROSPACE COMPONENTS (GlobeNewswire) -8.47%
Oct-11-23 09:00AM	SINTX Technologies Awarded Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants (GlobeNewswire)
Aug-31-23 03:26PM	11 ChatGPT Penny Stock Picks (Insider Monkey)
Aug-17-23 09:00AM	3DCERAM SINTO INC. and SINTX TECHNOLOGIES ANNOUNCE COLLABORATION TO DEVELOP MATERIALS AND TECHNOLOGIES FOR ADDITIVE MANUFACTURING OF ADVANCED CERAMICS (GlobeNewswire) -9.24%
Feb-14-23 09:00AM	SINTX TECHNOLOGIES ANNOUNCES ITS NEW UTAH ARMOR FACILITY IS FULLY OPERATIONAL (GlobeNewswire) -11.81%
Feb-10-23 01:52PM	SINTX Technologies Announces Closing of $12.0 Million Public Offering (GlobeNewswire) -9.93%
Feb-07-23 09:05PM	SINTX Technologies Announces Pricing of $12.0 Million Public Offering (GlobeNewswire) -18.60% -45.87%
Jan-19-23 09:00AM	SINTX Technologies Shares Select Preliminary Q4 2022 and Full Year 2022 Revenue Update (GlobeNewswire) +11.82%
Jan-06-23 09:00AM	SINTX TECHNOLOGIES REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE LISTING REQUIREMENT (GlobeNewswire)
Dec-21-22 09:00AM	SINTX TECHNOLOGIES AWARDED PHASE I CONTRACT FROM THE MISSILE DEFENSE AGENCY FOR ELECTROCHEMICAL MACHINING (GlobeNewswire) +57.16%
Dec-19-22 09:00AM	SINTX TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE DECEMBER 20, 2022 (GlobeNewswire)
Nov-16-22 05:27AM	Sintx Technologies Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Oct-26-22 09:00AM	SINTX TECHNOLOGIES AWARDED MULTI-YEAR DARPA CONTRACT TO DEVELOP CMCs AND HIGH TEMPERATURE COATINGS FOR TURBINE ENGINES (GlobeNewswire) +6.79%
Oct-13-22 08:30AM	SINTX Technologies, Inc. Announces Subscriptions of Approximately $4.7 Million from its Rights Offering (GlobeNewswire) -8.22%
Oct-11-22 09:00AM	SINTX TECHNOLOGIES RECEIVES PRODUCTION ORDER FOR AEROSPACE COMPONENTS (GlobeNewswire) -5.28%
Oct-04-22 11:05AM	SINTX ANNOUNCES NEW ANTIBACTERIAL BIOMEDICAL PATENTS AND EXPANSION OF INTELLECTUAL PROPERTY PORTFOLIO (GlobeNewswire) -7.23%
Sep-29-22 09:00AM	NATIONAL INSTITUTES OF HEALTH AWARDS GRANT TO SINTX TECHNOLOGIES FOR DEVELOPMENT OF 3D PRINTED ANTIMICROBIAL TRAUMA DEVICE (GlobeNewswire)
Sep-27-22 09:00AM	SINTX TECHNOLOGIES AWARDED DEPARTMENT OF ENERGY GRANT FOR DEVELOPMENT OF 3D PRINTED CERAMIC HEAT EXCHANGERS (GlobeNewswire) -6.31%
Sep-26-22 09:00AM	SINTX TECHNOLOGIES ANNOUNCES COMMENCEMENT OF RIGHTS OFFERING SUBSCRIPTION PERIOD AND UPDATED TERMS AND DATES OF ITS PREVIOUSLY ANNNOUNCED RIGHTS OFFERING (GlobeNewswire) -16.75%
Sep-12-22 09:00AM	SINTX TECHNOLOGIES INFORMS STOCKHOLDERS OF KEY DATES AND TERMS RELATED TO ANNOUNCED RIGHTS OFFERING (GlobeNewswire)
Sep-08-22 09:00AM	SINTX ANNOUNCES SUCCESSFUL FDA 510(k) PRE-SUBMISSION MEETING FOR SILICON NITRIDE-PEEK COMPOSITE SPINE IMPLANTS (GlobeNewswire)
Aug-23-22 09:00AM	Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings (GlobeNewswire) -5.45%
Jul-06-22 09:00AM	SINTX Technologies Acquires Technology Assessment and Transfer, Inc. (GlobeNewswire)
Mar-25-22 05:41PM	SINTX Technologies Issues 2022 10-K and Announces Investor Conference Call (GlobeNewswire)
Mar-10-22 09:00AM	National Institutes of Health Awards Grant to SINTX Technologies for Development of 3D Printed Craniomaxillofacial Devices (GlobeNewswire)
Feb-23-22 09:00AM	SINTX Announces Milestones In The Development and Testing of Antipathogenic Fabrics (GlobeNewswire)
Dec-31-21 09:00AM	SINTX Chief Scientific Officer Retires and Director of R&D Steps Into Leadership Role (GlobeNewswire)
Dec-08-21 09:00AM	SINTX Technologies Provides End of Year 2021 Business Update (GlobeNewswire)
Nov-16-21 09:00AM	SINTX Technologies Provides Update on SINTX Armor (GlobeNewswire)
Nov-05-21 09:00AM	SINTX Technologies Ends Patent License Agreement With O2TODAY (GlobeNewswire)
Oct-14-21 09:00AM	SINTX Technologies Shares Q3 2021 Revenue Update (GlobeNewswire)
Oct-06-21 09:00AM	SINTX Technologies Ships New FleX SN Porous and Laser-textured Spinal Implants (GlobeNewswire)
Sep-22-21 09:00AM	National Institute of Health Awards SINTX Technologies Phase 1 Grant for SN-PEEK 3D Printed Spinal Implants (GlobeNewswire)
Sep-15-21 04:01PM	SINTX Technologies Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum (GlobeNewswire)
Aug-25-21 11:53AM	SINTX Armor Ships First Order and Prepares for Move to Utah (GlobeNewswire)
Aug-18-21 09:00AM	SINTX Technologies Provides Update on Antipathogenic Business Segment (GlobeNewswire) +5.30%
Aug-05-21 01:02PM	SINTX Technologies Reassesses Exclusive Patent License with O2TODAY (GlobeNewswire)
Jul-27-21 09:00AM	SINTX Technologies Ships First Order of FleX SN-PEEK Composite (GlobeNewswire) +11.04%
Jul-22-21 09:00AM	SINTX Enters Ceramic Armor Market Through Purchase of Assets from B4C, LLC and Technology License from Precision Ceramics USA Inc. (GlobeNewswire)
Jun-30-21 09:00AM	SINTX Technologies Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY (GlobeNewswire) +7.26%
Jun-16-21 09:00AM	Oxford Performance Materials and SINTX Technologies Collaborate to Develop High Performance Coating Solution (GlobeNewswire)
Jun-09-21 09:00AM	SINTX Technologies Achieves Placement on the Russell Microcap Index (GlobeNewswire)
May-11-21 01:25PM	SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications (GlobeNewswire)
May-04-21 09:00AM	SINTX Technologies Files Multiple New U.S. and International Patent Applications (GlobeNewswire) +6.00%
Mar-30-21 11:30AM	SINTX Technologies, Inc. to Host Earnings Call (ACCESSWIRE)

SINTX Technologies, Inc. is a ceramics company, which engages in the development and commercialization of silicon nitride for medical and non-medical applications. It markets spinal fusion products and develops products for use in total hip and knee joint replacements. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in December 1996 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOYES JAY M	Director	Aug 26 '25	Buy	3.59	3,000	10,756	3,000	Aug 27 08:00 AM
Honigblum Gregg R.	Chief Investment Officer	Aug 26 '25	Buy	3.70	50,000	185,000	64,000	Aug 27 08:00 AM
Olson Eric K.	President and CEO	Aug 22 '25	Buy	3.58	10,475	37,470	24,975	Aug 25 05:14 PM
Anderson Mark Lewis	Director	Jun 18 '25	Buy	3.30	10,000	33,000	15,000	Jun 23 09:00 AM
Anderson Mark Lewis	Director	Apr 24 '25	Buy	2.36	5,000	11,800	5,000	May 14 07:00 AM
Honigblum Gregg R.	Chief Strategy Officer	Apr 22 '25	Buy	1.79	4,000	7,160	14,000	May 01 06:10 AM
Olson Eric K.	President and CEO	Apr 23 '25	Buy	1.94	14,264	27,680	14,500	Apr 30 02:25 PM
Olson Eric K.	President and CEO	Apr 22 '25	Buy	1.73	236	408	236	Apr 30 02:25 PM
Honigblum Gregg R.	Chief Strategy Officer	Apr 22 '25	Buy	1.77	10,000	17,666	10,000	Apr 30 02:24 PM
Tate Kerry	10% Owner	Feb 27 '25	Proposed Sale	4.38	157,249	688,751		Feb 27 10:46 AM

Open in Screener

PBYI

Puma Biotechnology Inc

Aug 29 • 09:43AM ET

4.99

Dollar change +0.02
Percentage change 0.31	%

Healthcare • Biotechnology • USA • NASD

PBYI Puma Biotechnology Inc daily Stock Chart

Peers: INCY MRNA EXEL SRPT BPMC FGEN NKTR KPTI LGND AFMD

| Held by: AVUV IWM VTI IWN VXF DFAS VTWO DFAT BSVO FDM

Index	RUT	P/E	5.09	EPS (ttm)	0.98	Insider Own	25.10%	Shs Outstand	49.89M	Perf Week	-5.04%
Market Cap	251.13M	Forward P/E	15.44	EPS next Y	0.32	Insider Trans	-1.43%	Shs Float	37.73M	Perf Month	60.31%
Enterprise Value	202.25M	PEG	-	EPS next Q	0.04	Inst Own	56.91%	Short Float	7.03%	Perf Quarter	52.00%
Income	48.45M	P/S	1.05	EPS this Y	-20.24%	Inst Trans	8.77%	Short Ratio	4.89	Perf Half Y	39.26%
Sales	238.06M	P/B	2.38	EPS next Y	-34.68%	ROA	24.23%	Short Interest	2.65M	Perf YTD	63.46%
Book/sh	2.10	P/C	2.56	EPS next 5Y	-17.35%	ROE	63.24%	52W High	6.07 -17.86%	Perf Year	96.28%
Cash/sh	1.95	P/FCF	5.68	EPS past 3/5Y	- -	ROIC	41.92%	52W Low	2.22 124.07%	Perf 3Y	53.88%
Dividend Est.	-	EV/EBITDA	3.53	Sales past 3/5Y	-3.08% -3.28%	Gross Margin	72.33%	Volatility	5.93% 9.44%	Perf 5Y	-52.61%
Dividend TTM	-	EV/Sales	0.85	EPS Y/Y TTM	429.84%	Oper. Margin	19.35%	ATR (14)	0.33	Perf 10Y	-94.47%
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	8.63%	Profit Margin	20.35%	RSI (14)	60.74	Recom	4.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.73	EPS Q/Q	224.52%	SMA20	6.53%	Beta	1.40	Target Price	3.00
Payout	0.00%	Debt/Eq	0.47	Sales Q/Q	11.37%	SMA50	27.68%	Rel Volume	0.34	Prev Close	4.97
Employees	172	LT Debt/Eq	0.10	Earnings	Aug 07 AMC	SMA200	50.51%	Avg Volume	542.66K	Price	4.99
IPO	Apr 20, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	41.18% -5.38%	Trades		Volume	14,988	Change	0.31%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$11
Jun-25-20	Resumed	BofA/Merrill	Underperform	$9
Oct-08-19	Downgrade	Goldman	Neutral → Sell	$24 → $8
May-10-19	Downgrade	Citigroup	Buy → Neutral	$24
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $20
Jan-17-19	Initiated	Leerink Partners	Mkt Perform	$21
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight	$75
Sep-17-18	Initiated	Goldman	Sell	$42
May-11-18	Reiterated	Stifel	Buy	$95 → $87
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform	$92 → $108
Nov-10-17	Reiterated	Citigroup	Buy	$156 → $164
Oct-02-17	Reiterated	Stifel	Buy	$110 → $130
Sep-11-17	Reiterated	Credit Suisse	Outperform	$118 → $136
Jul-10-17	Resumed	Leerink Partners	Outperform	$115
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform	$60 → $88
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform	$40 → $60

Show Previous Ratings

Aug-28-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.83%
Aug-12-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
09:15AM	Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? (Zacks)
09:11AM	Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT (Insider Monkey)
05:00PM	Loading…
Aug-08-25 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.16% +31.44%
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
Aug-07-25 05:55PM	Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:56PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Aug-06-25 06:05PM	Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-24-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results (Business Wire)
Jul-15-25 08:31AM	Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns (Zacks)
Jul-14-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
Jul-10-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
10:31AM	Loading…
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Jun-25-25 11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 08:50AM	Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain (Zacks)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-12-25 11:30AM	Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? (Zacks)
Jun-11-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
05:33PM	Loading…
Jun-04-25 05:33PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
May-28-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
May-26-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
May-12-25 08:50AM	Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock (Zacks)
May-09-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks) -5.21%
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
03:39AM	Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
May-08-25 05:55PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
04:52PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
May-07-25 05:20PM	Puma Biotechnology Q1 2025 Earnings Preview (Seeking Alpha)
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-05-25 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-01-25 08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)
Apr-30-25 12:00PM	Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
06:00AM	Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX (neratinib) for Breast Cancer Patients (GlobeNewswire)
Apr-28-25 03:03PM	Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Apr-24-25 04:11PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Apr-21-25 09:13AM	Is the Options Market Predicting a Spike in Puma Biotechnology Stock? (Zacks)
Apr-11-25 01:20PM	Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential (Seeking Alpha)
Apr-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-25 09:00AM	Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 12:23PM	Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why (Zacks)
Mar-18-25 04:35AM	Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-05-25 06:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:30PM	Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference (Business Wire)
Mar-03-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks) -6.42%
Feb-28-25 12:04PM	Q4 2024 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +19.73%
02:34AM	Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-27-25 05:29PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance) +7.94%
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 04:15PM	Puma Biotechnology to Present at TD Cowens 45th Annual Health Care Conference (Business Wire)
Feb-13-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-05-25 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-03-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.45% +20.34%
Jan-01-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Dec-23-24 09:01AM	Puma Biotechnologys NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation (Business Wire)
Dec-04-24 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-28-24 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Nov-21-24 05:38AM	Puma commences Phase II trial of alisertib for breast cancer treatment (Clinical Trials Arena)
Nov-20-24 08:57AM	Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer (Business Wire)
Nov-08-24 02:27AM	Puma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Nov-07-24 05:33PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-24-24 04:07PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Business Wire) +5.36%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-03-24 04:15PM	Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct)
Aug-06-24 05:23PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.26% -7.44%
Aug-02-24 10:07AM	Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected (Zacks) +9.43%
Aug-01-24 05:04PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Jul-23-24 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jul-18-24 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results (Business Wire)
Jul-02-24 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.49%
Jun-07-24 05:37PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 02:33PM	Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer (Business Wire)
Jun-02-24 10:01AM	Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) (Business Wire)
May-28-24 09:00AM	Puma Biotechnology to Join Russell 3000 Index (Business Wire)
May-24-24 11:57AM	Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why (Zacks)
May-23-24 05:15PM	Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting (Business Wire) -5.67%
May-20-24 09:59AM	Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options (Zacks) +6.72%
May-03-24 01:09PM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:31AM	Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat (Zacks)
04:02AM	Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cesano Alessandra	Director	Jul 18 '25	Sale	3.37	27,000	90,909	41,850	Jul 22 07:51 PM
Cesano Alessandra	Director	Jul 18 '25	Proposed Sale	3.37	27,000	90,909		Jul 18 04:16 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 08 '25	Sale	3.53	5,587	19,739	208,164	Jul 10 08:56 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 09 '25	Sale	3.54	3,935	13,910	204,229	Jul 10 08:56 PM
HUNT DOUGLAS M	See Remarks	Jul 08 '25	Sale	3.53	4,374	15,453	168,337	Jul 10 08:52 PM
HUNT DOUGLAS M	See Remarks	Jul 09 '25	Sale	3.54	3,443	12,171	164,894	Jul 10 08:52 PM
AUERBACH ALAN H	President and CEO	Jul 08 '25	Sale	3.53	25,592	90,417	7,202,481	Jul 10 08:49 PM
AUERBACH ALAN H	President and CEO	Jul 09 '25	Sale	3.54	21,580	76,285	7,180,901	Jul 10 08:49 PM
NOUGUES MAXIMO F	Officer	Jul 09 '25	Proposed Sale	3.54	3,935	13,910		Jul 09 04:48 PM
AUERBACH ALAN H	Officer	Jul 09 '25	Proposed Sale	3.54	21,580	76,285		Jul 09 04:36 PM
HUNT DOUGLAS M	Officer	Jul 09 '25	Proposed Sale	3.54	3,443	12,171		Jul 09 04:27 PM
AUERBACH ALAN H	Officer	Jul 08 '25	Proposed Sale	3.53	25,592	90,424		Jul 08 04:41 PM
NOUGUES MAXIMO F	Officer	Jul 08 '25	Proposed Sale	3.53	5,587	19,741		Jul 08 04:39 PM
HUNT DOUGLAS M	Officer	Jul 08 '25	Proposed Sale	3.53	4,374	15,455		Jul 08 04:29 PM
WILSON TROY EDWARD	Director	Jun 13 '25	Sale	3.40	10,800	36,720	43,550	Jun 17 07:55 PM
Stuglik Brian M	Director	Jun 13 '25	Sale	3.39	8,100	27,459	94,958	Jun 17 07:52 PM
Senderowicz Adrian	Director	Jun 13 '25	Sale	3.40	27,000	91,800	27,000	Jun 17 07:49 PM
MOYES JAY M	Director	Jun 13 '25	Sale	3.40	22,000	74,800	53,322	Jun 17 07:46 PM
Dorval Allison	Director	Jun 13 '25	Sale	3.40	11,610	39,474	75,390	Jun 17 07:43 PM
Cesano Alessandra	Director	Jun 13 '25	Sale	3.40	12,150	41,310	68,850	Jun 17 07:41 PM
WILSON TROY EDWARD	Director	Jun 13 '25	Proposed Sale	3.40	10,800	36,678		Jun 13 04:15 PM
Senderowicz Adrian	Director	Jun 13 '25	Proposed Sale	3.40	27,000	91,767		Jun 13 04:11 PM
Dorval Allison	Director	Jun 13 '25	Proposed Sale	3.40	11,610	39,437		Jun 13 04:10 PM
Cesano Alessandra	Director	Jun 13 '25	Proposed Sale	3.40	12,150	41,285		Jun 13 04:09 PM
Stuglik Brian M	Director	Jun 13 '25	Proposed Sale	3.39	8,100	27,497		Jun 13 04:07 PM
MOYES JAY M	Director	Jun 13 '25	Proposed Sale	3.40	22,000	74,756		Jun 13 04:04 PM
Ludwig Jeffrey Jerome	Former Officer	May 21 '25	Proposed Sale	3.42	55,882	191,310		May 21 03:00 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 02 '25	Sale	3.15	10,227	32,232	152,295	Jan 03 07:33 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jan 02 '25	Sale	3.15	9,437	29,743	108,951	Jan 03 07:31 PM
HUNT DOUGLAS M	See Remarks	Jan 02 '25	Sale	3.15	8,633	27,209	124,594	Jan 03 07:28 PM
AUERBACH ALAN H	President and CEO	Jan 02 '25	Sale	3.15	33,841	106,657	7,029,674	Jan 03 07:12 PM
NOUGUES MAXIMO F	Officer	Jan 02 '25	Proposed Sale	3.05	10,227	31,192		Jan 02 08:37 PM
Ludwig Jeffrey Jerome	Officer	Jan 02 '25	Proposed Sale	3.05	9,437	28,783		Jan 02 08:34 PM
HUNT DOUGLAS M	Officer	Jan 02 '25	Proposed Sale	3.05	8,633	26,331		Jan 02 08:33 PM
AUERBACH ALAN H	Officer	Jan 02 '25	Proposed Sale	3.05	33,841	103,215		Jan 02 08:30 PM

SINT

SINTX Technologies Inc

PBYI

Puma Biotechnology Inc

Upgrade your FINVIZ experience